# US 2003/0215440 A1 · Antithrombotic thrombin variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215440 A1
- Document ID: US20030215440A1
- Status: Published application
- Kind: A1
- Application number: 10/165,442
- Filed: 2002-06-07
- Published: 2003-11-20
- Earliest claimed: 2001-06-08
- Assignees: Emory University
- Inventors: Andras Gruber; Stephen R. Hanson; Enrico Di Cera
- Web page: https://patentgrep.com/patent/US20030215440A1

## CPC

- C12N 9/6464: {Protein C (3.4.21.69)}
- C12N 9/6429: {Thrombin (3.4.21.5)}
- C12Q 1/40: involving amylase
- C12Y 304/21005: Thrombin (3.4.21.5)
- C12Y 304/21069: Protein C activated (3.4.21.69)
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptidess that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.

## Claims

### Claim 1

A variant thrombin comprising an amino acid sequence having the substitutions W215A and E217A, wherein the amino acid sequence is at least 80% identical to the sequence set forth in SEQ ID NO: 3.

### Claim 2 (depends on 1)

The variant thrombin according to claim 1 comprising a thrombin B-chain comprising the amino acid sequence as set forth in SEQ ID NO: 4.

### Claim 3 (depends on 1)

The variant thrombin according to claim 1, wherein the variant thrombin is encoded by a nucleic acid comprising the sequence as set forth in SEQ ID NO: 5, or a degenerate variant thereof.

### Claim 4 (depends on 2)

The variant thrombin according to claim 2, wherein the variant thrombin is encoded by a nucleic acid comprising the sequence as set forth in SEQ ID NO: 6, or a degenerate variant thereof.

### Claim 5 (depends on 1)

The variant thrombin according to claim 1 having a PA/FC ration greater than 1.0.

### Claim 6 (depends on 1)

The variant thrombin according to claim 1 having a PA/FC ration greater than 150.

### Claim 7 (depends on 1)

The variant thrombin according to claim 1, wherein the variant thrombin is expressed from a recombinant nucleic acid within a cell.

### Claim 8 (depends on 7)

The variant thrombin according to claim 7, wherein the recombinant nucleic acid comprises a sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6, or a degenerate variant thereof.

### Claim 9

A nucleic acid encoding a variant thrombin and comprising a nucleic acid selected from SEQ ID NO: 5 and SEQ ID NO: 6, or a degenerate variant thereof.

### Claim 10 (depends on 9)

The nucleic acid according to claim 9, wherein the nucleic acid is in an expression cassette.

### Claim 11 (depends on 10)

The nucleic acid according to claim 10, wherein the expression cassette is in a vector.

### Claim 12 (depends on 9)

A cell having a nucleic acid comprising the sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6, or a degenerate variant thereof, and capable of producing a variant thrombin protein according to claim 9.

### Claim 13

A physiologically acceptable composition comprising:
(a) a variant thrombin, wherein the variant prothrombin has the amino acid substitution W215A and is at least 80% identical to the amino acid sequence as set forth in SEQ ID NO: 1; and
(b) at least one pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The physiologically acceptable composition according to claim 13, wherein the variant thrombin comprises the amino acid sequence set forth in SEQ ID NO: 1.

### Claim 15 (depends on 13)

The physiologically acceptable composition according to claim 13, wherein the variant thrombin comprises the amino acid sequence set forth in SEQ ID NO: 2.

### Claim 16

A physiologically acceptable composition comprising:
(a) a variant thrombin, wherein the variant prothrombin has the amino acid substitutions W215A and E217A, and is at least 80% identical to the amino acid sequence as set forth in SEQ ID NO: 3; and
(b) at least one pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The physiologically acceptable composition according to claim 16, wherein the variant thrombin has the amino acid substitutions W215A and E217A, and comprises the amino acid sequence set forth in SEQ ID NO: 3.

### Claim 18 (depends on 16)

The physiologically acceptable composition according to claim 16, wherein the variant thrombin has the amino acid substitutions W215A and E217A, and comprises the amino acid sequence set forth in SEQ ID NO: 4.

### Claim 19

A method of inhibiting the formation of a thrombus, comprising the steps of:
(a) delivering to the blood of an animal or human a physiologically acceptable composition comprising an effective amount of a variant thrombin with substantially reduced procoagulant activity, wherein the variant thrombin has the amino acid substitution W215A and comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 1; and
(b) allowing the variant thrombin to activate protein C, thereby inhibiting thrombus formation.

### Claim 20 (depends on 19)

The method according to claim 19, further comprising the step of administering to the animal or human a variant prothrombin capable of cleavage to the variant thrombin.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the variant thrombin comprises the amino acid sequence set forth in SEQ ID NO: 1.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the variant thrombin comprises the amino acid sequence set forth in SEQ ID NO: 2.

### Claim 23 (depends on 19)

The method according to claim 19, wherein the variant thrombin further comprises the amino acid substitution E217A.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the variant thrombin comprises the amino acid sequence as set forth in SEQ ID NO: 3.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the variant thrombin is a variant thrombin B-chain comprising an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 4.

### Claim 26 (depends on 19)

The method according to claim 19, wherein the variant thrombin has a PA/FC ratio greater than 1.0.

### Claim 27 (depends on 19)

The method according to claim 19, wherein the variant thrombin has a PA/FC ratio greater than 150.

### Claim 28 (depends on 19)

The method according to claim 19, wherein the physiologically acceptable composition further comprises a pharmaceutically acceptable carrier.

### Claim 29 (depends on 19)

The method according to claim 19, wherein the blood is in a blood vessel selected from the group consisting of an artery, an arteriole, a venule, a vein, a capillary, a fistula and a heart.

### Claim 30 (depends on 19)

The method according to claim 19, wherein the blood is in a cardiovascular device connected to the vascular system of an animal or human and selected from the group consisting of a stent, a vascular graft, an arterio-venous shunt, a cardiopulmonary bypass device, a cardiac assist device, a hemodialyzer and an artificial organ.

### Claim 31 (depends on 19)

The method according to claim 19, wherein the effective amount of the variant thrombin is delivered to the lumen of a blood vessel of a recipient animal or human.

### Claim 32 (depends on 19)

The method according to claim 19, wherein the effective amount of the variant thrombin is delivered to the blood as a bolus amount.

### Claim 33 (depends on 19)

The method according to claim 19, wherein the effective amount of the variant thrombin is delivered to the blood over a sustained period.

### Claim 34 (depends on 19)

The method according to claim 19, wherein the effective amount of the variant thrombin is delivered to blood of the animal or human by a route selected from the group consisting of an intravascular, an intraperitoneal, an intramuscular, an intrathecal, an intraarticular, an intrapulmonary, an intraperitoneal, a retroperitoneal, an intrapleural, a subcutaneous, a percutaneous, a transmucosal, an oral, a gastro-intestinal, and an intraocular route.

### Claim 35 (depends on 19)

The method according to claim 19, wherein the effective amount of the variant thrombin is delivered to the animal or human by an intravascular route.

### Claim 36 (depends on 19)

The method according to claim 19, wherein the effective amount of the variant thrombin is delivered to the animal or human by an intravascular infusion route selected from the group consisting of an intravascular injection, an intravascular drip and a catheter.

### Claim 37 (depends on 19)

The composition according to claim 19, wherein the effective amount of the variant thrombin is administered at the dosage of between about 0.1 μg/kg/day to about 30 mg/kg/day.

### Claim 38

A method of inhibiting the formation of a thrombus, comprising the steps of:
(a) delivering to the blood of an animal or human a physiologically acceptable composition comprising an effective amount of a variant thrombin with substantially reduced procoagulant activity, wherein the variant thrombin has the amino acid substitutions W215A and comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 1; and
(b) allowing the variant thrombin to activate protein C, thereby inhibiting thrombus formation.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the variant thrombin is a variant thrombin B-chain comprising an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 2.

### Claim 40

A method of inhibiting the formation of a thrombus, comprising the steps of:
(a) delivering to the blood of an animal or human a physiologically acceptable composition comprising an effective amount of a variant thrombin with substantially reduced procoagulant activity, wherein the variant thrombin has the amino acid substitutions W215A and E217A and comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 3; and
(b) allowing the variant thrombin to activate protein C, thereby inhibiting thrombus formation.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the variant thrombin is a variant thrombin B-chain comprising an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 4.

### Claim 42 (depends on 19)

A kit comprising a variant thrombin comprising an amino acid sequence selected from SEQ ID NOS: 1 and 2, and packaging comprising instructions for using the variant prothrombin to induce antithrombotic activity in a recipient animal or human according to the method of claim 19.

### Claim 43 (depends on 42)

The kit according to claim 42, further consisting a pharmaceutically acceptable carrier and instructions for use in delivering the variant prothrombin to an animal or human.

### Claim 44 (depends on 19)

A kit comprising a variant thrombin with reduced procoagulant and platelet activating activity and comprising an amino acid sequence selected from SEQ ID NOS: 3 and 4, and packaging comprising instructions for using the variant thrombin as an antithrombotic agent in a recipient animal or human according to the method of claim 19.

### Claim 45 (depends on 44)

The kit according to claim 44, further comprising a pharmaceutically acceptable carrier and instructions for use in delivering the variant thrombin to an animal or human.

### Claim 46

A method to determine the endogenous antithrombotic potential of the protein C system of an animal or patient, comprising the steps of:
(a) administering to an animal or human an effective dose of a variant thrombin having a substantially reduced fibrinogen cleavage activity and capable of activating protein C;
(b) obtaining from the animal or human a blood sample, and measuring the coagulation rate or APC amidolytic activity thereof; and
(c) comparing the coagulation rate or APC amidolytic activity to the coagulation rate or APC amidolytic activity of a standard, thereby indicating the endogenous antithrombotic potential of the protein C system of the animal or human.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the variant thrombin comprises an amino acid sequence selected from SEQ ID NOS: 1 and 3.

### Claim 48 (depends on 53)

The method according to claim 53, further wherein the variant thrombin is a variant thrombin B-chain comprising an amino acid sequence at least 80% identical to the amino acid sequence selected from SEQ ID NO: 2 and SEQ ID NO: 4.

### Claim 49 (depends on 49)

A kit comprising a variant thrombin with reduced procoagulant activity and comprising the amino acid sequence selected from SEQ ID NOS: 1, 2, 3 and 4, and packaging comprising instructions for using the variant thrombin to determine the endogenous antithrombotic potential of the protein C system of an animal or human according to claim 49.

### Claim 50

A method for producing activated protein C, comprising the steps of:
(a) obtaining an sample of protein C;
(b) incubating the sample of protein C with a variant thrombin with reduced procoagulant activity, wherein the variant thrombin has the amino acid substitution W215A and comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 1; and
(c) cleaving the isolated protein C by the variant thrombin, thereby yielding activated protein C.

### Claim 51 (depends on 50)

The method according to claim 50, further comprising the step of isolating the activated protein C substantially free of the variant thrombin and from fibrinogen cleavage activity.

### Claim 52 (depends on 50)

The method according to claim 50, wherein the variant thrombin is a variant thrombin B-chain comprising an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 2.

### Claim 53 (depends on 57)

The method according to claim 57, wherein the variant thrombin further comprises the amino acid substitution E217A.

### Claim 54 (depends on 57)

The method according to claim 57, wherein the variant thrombin comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 3.

### Claim 55 (depends on 57)

The method according to claim 57, wherein the variant thrombin is a variant thrombin B-chain comprising an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 4:

### Claim 56

A method of determining the protein C activity in an individual, comprising the steps of:
(a) obtaining a blood sample from an individual;
(b) contacting the blood sample with a variant thrombin substantially free of fibrinogen cleavage activity and capable of protein C activation; and
(c) measuring the level of activated protein C in the blood sample.

### Claim 57 (depends on 62)

The method of claim 62, further comprising the step of adding to the variant thrombin a thrombomodulin analog, calcium ions, and an optional activated protein C chromogenic substrate.

### Claim 58 (depends on 62)

The method of claim 62, wherein the variant thrombin is selected from SEQ ID NOS: 1, 2, 3 and 4.
